RAPT Therapeutics, Inc. Common Stock (RAPT)

RAPT Therapeutics plans to raise approximately $250 million through a public offering of 8,333,334 common stock shares at $30.00 per share, with potential additional shares through underwriters' option.

Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival b...

U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday. Shares of Rivian Automotive, Inc. (NASDAQ: RIVN) fell sharply in today’s pre-market trading after the company reported a wider-than-expected loss for its fourth quarter and announced plans to reduce its salaried workforce by around 1...

RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation drug.

The company reported great results from an early-stage study of its experimental atopic dermatitis drug.